Security
Advanced Biomed Inc. Common Stock · ADVB
ADVBNASDAQCommon stockCurrentCIK 1941029Updated Oct 14, 2026
ADVB price & chart
Loading TradingView…
NASDAQ:ADVB on TradingView ↗About the company
We are a holding company incorporated in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor technology and biotechnology. This includes complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic integrated semiconductor sensors, related application modules, and key components of medical testing equipment. We have also developed a series of medical testing equipment and related products by integrating various functions of microfluidic modules, automation software, and hardware. Our technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer through the det…
In the news
No coverage from other publishers is available.
SEC disclosures
Recent filings
10-K filing
NT 10-K filing
SCHEDULE 13G - filed by ADVANCE ON VENTURES Ltd regarding Advanced Biomed Inc.
RW filing
Termination of a Material Definitive Agreement
Items 1.02, 9.01
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
Entry into a Material Definitive Agreement
Items 1.01, 9.01
DEF 14A filing
10-Q filing
Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 2.01, 3.02, 5.02, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 10,646,324Source | 8,287,598Source | — | 10,850,712Source | 4,504,152Source | — | 6,242,970Source | — | 13,750,716Source | 6,512,343Source |
| Property, Plant and Equipment, NetUSD | 87,280Source | 355,274Source | — | 97,100Source | 401,007Source | — | 281,270Source | — | — | 331,346Source |
| Current assets: | ||||||||||
| Assets, CurrentUSD | 10,526,309Source | 7,731,148Source | — | 10,731,565Source | 3,138,891Source | — | 5,844,133Source | — | 13,749,512Source | 6,032,571Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,923,612Source | 2,547,048Source | — | 8,126,899Source | 481,656Source | — | 3,187,614Source | — | 13,363,977Source | 3,128,656Source |
| Operating Lease, Right-of-Use AssetUSD | 30,551Source | 180,851Source | — | 21,091Source | 241,267Source | — | 42,797Source | — | — | 65,399Source |
| Other Assets, NoncurrentUSD | 2,184Source | — | — | 956Source | — | — | 74,770Source | — | — | 83,027Source |
| LIABILITIES AND EQUITY | ||||||||||
| LiabilitiesUSD | 1,436,587Source | 4,157,815Source | — | 1,369,070Source | 3,885,120Source | — | 3,238,846Source | — | 1,473,989Source | 3,034,779Source |
| Stockholders’ equity: | ||||||||||
| Common Stock, Value, IssuedUSD | 1,382Source | 21,640Source | — | 21,640Source | 20,000Source | — | 21,640Source | — | 1,652Source | 21,640Source |
| Retained Earnings (Accumulated Deficit)USD | -13,250,966Source | -18,531,433Source | — | -12,762,024Source | -17,147,559Source | — | -19,619,945Source | — | -12,555,967Source | -19,233,044Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 843,785Source | 1,292,298Source | — | 874,748Source | 1,252,602Source | — | 1,255,151Source | — | 968,876Source | 1,341,690Source |
| Stockholders' Equity Attributable to ParentUSD | 9,209,737Source | 4,129,783Source | -497,797Source | 9,481,642Source | 619,032Source | 196,841Source | 3,004,124Source | 1,093,830Source | 12,276,727Source | 3,477,564Source |
| Additional Paid in Capital, Common StockUSD | 21,615,536Source | 21,347,278Source | — | 21,347,278Source | 16,493,989Source | — | 21,347,278Source | — | 23,862,166Source | 21,347,278Source |
| Liabilities and EquityUSD | 10,646,324Source | 8,287,598Source | — | 10,850,712Source | 4,504,152Source | — | 6,242,970Source | — | 13,750,716Source | 6,512,343Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | 1,425,684Source | 4,113,343Source | — | 1,253,574Source | 3,828,794Source | — | 3,044,952Source | — | 1,473,989Source | 2,889,128Source |
| Operating Lease, Liability, CurrentUSD | 18,608Source | 138,357Source | — | 19,661Source | 233,701Source | — | 27,934Source | — | — | 35,811Source |
| Accounts Payable, CurrentUSD | 377,264Source | 618,520Source | — | 369,293Source | 617,865Source | — | 641,587Source | — | — | 632,697Source |
| Operating Lease, Liability, NoncurrentUSD | 10,903Source | 44,472Source | — | 1,431Source | 56,326Source | — | 2,935Source | — | — | 5,879Source |
| Additional Financial Items | ||||||||||
| Accrued Liabilities, CurrentUSD | 238,538Source | — | — | 224,038Source | — | — | — | — | 231,674Source | — |
| Intangible Assets, Net (Excluding Goodwill) | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | — | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 1,734,009Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,205Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -610,342Source | -29,680Source | -1,946,943Source | -5,825,055Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,771Source | -19,978Source | -2,506,087Source | -31,650Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,771Source | 19,978Source | — | 31,650Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 447,462Source | 392,525Source | 1,967,972Source | 5,934,301Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -247,396Source | 39,019Source | -2,518,380Source | 295,942Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,602,697Source | 3,176,462Source | 2,604,666Source | 2,647,656Source | 2,656,519Source | 2,646,992Source | 385,535Source | 2,903,915Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -82,745Source | -303,848Source | -10,479Source | 218,346Source |
| Additional Financial Items | ||||||||||
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | — | 7,346,684Source | — | — | — | 14,015,417Source | — |
| DepreciationUSD | — | — | 9,326Source | 22,507Source | 14,462Source | 21,983Source | 47,992Source | 67,290Source | — | 224,832Source |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | — | — | — | — | — | — | — | — | 14,015,417Source | — |
| General and Administrative ExpenseUSD | — | — | 276,610Source | 347,541Source | 210,311Source | 67,667Source | 287,922Source | 338,324Source | 4,627,170Source | 2,111,265Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -488,942Source | -1,197,499Source | 7,002,178Source | -579,494Source | — | — | -6,261,276Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -186,375Source | -144,257Source | -328,410Source | — | — | 12,938,353Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,205Source | — |
| Investment Income, InterestUSD | — | — | — | — | 9,206Source | 15,377Source | 448Source | 10Source | — | 24,915Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -488,942Source | -1,383,874Source | 6,857,921Source | -907,904Source | -386,901Source | -265,580Source | 6,677,077Source | -3,258,969Source |
| Nonoperating Income (Expense)USD | — | — | 30,894Source | -629,992Source | 7,398,820Source | -299,430Source | 137,013Source | 254,447Source | -28,939Source | -237,933Source |
| Operating ExpensesUSD | — | — | 519,836Source | 567,507Source | 396,642Source | 280,064Source | 523,914Source | 520,027Source | 6,361,179Source | 3,021,036Source |
| Other Nonoperating Income (Expense)USD | — | — | 31,006Source | -629,992Source | 42,930Source | -314,807Source | 136,565Source | 254,437Source | -21,925Source | -262,848Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 248,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | 127,637Source | — |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | — | — | — | — |
| Amortization of Intangible Assets | — | — | — | —Source | — | —Source | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 127,637Source | — |
| Operating Income (Loss)USD | — | — | — | — | — | — | — | — | -6,233,542Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 31,006Source | -629,992Source | 42,930Source | -314,807Source | 136,565Source | 254,437Source | -21,925Source | -262,848Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -488,942Source | -1,197,499Source | 7,002,178Source | -579,494Source | -386,901Source | -265,580Source | -6,262,481Source | -3,258,969Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,205Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -488,942Source | -1,383,874Source | 6,857,921Source | -907,904Source | -386,901Source | -265,580Source | 6,677,077Source | -3,258,969Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.38Source | -1.35Source | 0.31Source | -0.05Source | -0.02Source | -0.01Source | 5.33Source | -0.16Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.38Source | -1.35Source | 0.31Source | -0.05Source | -0.02Source | -0.01Source | 5.33Source | -0.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,284,923Source | 1,023,955Source | 21,640,000Source | 20,000,000Source | 21,640,000Source | 20,000,000Source | 1,252,727Source | 20,525,699Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,284,923Source | 1,023,955Source | 21,640,000Source | 20,000,000Source | 21,640,000Source | 20,000,000Source | 1,252,727Source | 20,525,699Source |
| Additional Financial Items | ||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 47,992Source | 102,218Source | — | 343,830Source |
| General and Administrative ExpenseUSD | — | — | 276,610Source | 347,541Source | 210,311Source | 67,667Source | 287,922Source | 338,324Source | 4,627,170Source | 2,111,265Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -488,942Source | -1,197,499Source | 7,002,178Source | -579,494Source | — | — | -6,261,276Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.38Source | -1.17Source | 0.32Source | -0.03Source | — | — | -5Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.38Source | -1.17Source | 0.32Source | -0.03Source | — | — | -5Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -186,375Source | -144,257Source | -328,410Source | — | — | 12,938,353Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -112Source | — | — | — | — | — | -7,014Source | — |
| Investment Income, InterestUSD | — | — | — | — | 9,206Source | 15,377Source | 448Source | 10Source | — | 24,915Source |
| Nonoperating Income (Expense)USD | — | — | 30,894Source | -629,992Source | 7,398,820Source | -299,430Source | 137,013Source | 254,447Source | -28,939Source | -237,933Source |
| Operating ExpensesUSD | — | — | 519,836Source | 567,507Source | 396,642Source | 280,064Source | 523,914Source | 520,027Source | 6,361,179Source | 3,021,036Source |
| Research and Development ExpenseUSD | — | — | 243,226Source | 219,966Source | 186,331Source | 212,397Source | 235,992Source | 181,703Source | — | 909,771Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | 127,637Source | — |
| Amortization of Intangible Assets | — | — | — | —Source | — | —Source | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | —Source | — | — | — | — |
| Income (Loss) Attributable to Parent, before Tax | — | — | — | — | — | — | — | — | — | — |
| Interest Income, Other | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-288907
Registration 333-272110
- Deal price
- 4.0
- Offering price
- $4.00
- Ticker
- ADVB
Filing attachments
ea030745701ex4-2.htm · 10-K · 2026-10-13
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General The following description of the capital stock of Advanced Biomed Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our articles of incorporation and bylaws, as amended from time to time, is a summary and is qualified in its entirety by reference to the full text of our articles of incorporation and bylaws. Common Stock Advanced Biomed Inc. is authorized to issue 400,000,000 shares of common stock, par value $0.001 per sha…
Read attachment ↗ea027844801ex99-1.htm · 8-K · 2026-02-26
EX-99.1 2 ea027844801ex99-1.htm PRESS RELEASE ISSUED BY ADVANCED BIOMED INC., DATED FEBRUARY 18, 2026 Exhibit 99.1 Advanced Biomed Inc. Announces 1 for 20 Share Consolidation Tainan City, Taiwan, - February 18, 2026 - Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company’s …
Read attachment ↗ea027115701ex99-1_advanced.htm · 8-K · 2025-12-30
EX-99.1 3 ea027115701ex99-1_advanced.htm PRESS RELEASE DATED DECEMBER 30, 2025 Exhibit 99.1 Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) - Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an …
Read attachment ↗ea025811601ex99-1_advanced.htm · 8-K · 2025-09-19
EX-99.1 2 ea025811601ex99-1_advanced.htm PRESS RELEASE, DATED SEPTEMBER 19, 2025 Exhibit 99.1 Advanced Biomed Inc. Announces Launch of A+PerfusC™ - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery Tainan City, Taiwan, - September 19, 2025 - Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnost…
Read attachment ↗ea024661301ex99-1_advanced.htm · S-1 · 2025-07-23
EX-99.1 23 ea024661301ex99-1_advanced.htm CODE OF BUSINESS CONDUCT AND ETHICS OF THE REGISTRANT Exhibit 99.1 CODE OF BUSINESS CONDUCT AND ETHICS Advanced Biomed Inc. (the “Company” or “Advanced Biomed”) has enjoyed a reputation as a company of high integrity. The Company has worked hard to earn the respect of customers, suppliers, and the public. This Code of Business Conduct and Ethics (“Code”) embodies Advanced Biomed’s commitment to continue to enjoy this fine reputation into the future…
Read attachment ↗